Fresenius : Factsheet H1/22 (PDF)

| Factsheet H1/ 22

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Frese- nius focuses on hospital operations. We also manage projects and provide ­services for hospitals and other health care facilities. More than 300,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions		H1 / 22			H1 / 21		Change		FY / 21
Sales and Earnings
Sales	19,738	18,230	8%		37,520
EBIT 1	2,003	2,042	-2%		4,252
Net income 1, 2	913	911	0%		1,867
Earnings per share in € 1, 2	1.63	1.63	0%		3.35
Balance sheet and cash flow
Total assets	76,112				6%		71,962
Non-current assets	57,294				5%		54,501
Equity 3	32,033				9%		29,288
Equity ratio 3	42.1%							40.7%
Net debt / EBITDA 1, 4	3,72							3.51
Investments 5	1,210	1,533	-21%		3,117
Operating cash flow	1,118	2,103	-47%		5,078
Operating cash flow in %
of sales	5.7%			11.5 %				13.5%
Profitability
EBIT margin 1	10.1%	11.2%				11.3%
Return on equity after taxes
(ROE) 1, 2	9.0%	10.4%				9.8%
Return on operating assets
(ROOA) 1	6.1%	6.7%				6.5%
Return on invested capital
(ROIC) 1	5.5%	6.2%				5.9%
Employees		318.647							316,078

1. Before special items
2. Net income attributable to shareholders of Fresenius SE & Co. KGaA
3. Including noncontrolling interests
4. At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions / divestitures
5. Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

32% 1

100%

100%

77%

Fresenius

Fresenius

Fresenius

Fresenius

Medical Care

Kabi

Helios

Vamed

1 As of June 30, 2022

BUSINESS SEGMENTS

€ in millions	H1/ 22		H1 / 21		Change		FY/ 21
		Sales	9,305	8,530	9%	17,619
		EBIT 1	688	898	-23%	1,852
		Sales	3,743	3,516	6%	7,193
		EBIT 2	564	574	-2%	1,153
		Sales	5,856	5,387	9%	10,891
		EBIT 2	609	566	8%	1,127
		Sales	1,075	1,033	4%	2,297
		EBIT 2		19	12	58%	101

1 Reported

2 Before special items

SALES BY REGION

Latin America and

Others 6%

Asia-Pacific10%

Europe 45%

North America 39%

H1 / 22: € 19.7 billion

• Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of June 30, 2022, Fresenius Medical Care was treating 345,687 patients in 4,163 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.
• Fresenius Kabi offers intravenously administered generic drugs,
  clinical­ nutrition and infusion therapies for seriously and chroni- cally ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
• Fresenius Helios is Europe's leading private hospital operator. The company comprises Helios Germany, Helios Spain and Helios Fertility. Helios Germany operates 87 hospitals, ~130 outpatient centers and 6 prevention centers. Helios Spain operates 50 hospitals, 97 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with
  8 hospitals and as a provider of medical diagnostics. Helios Fertility offers a wide spectrum of state-of-the-art services in the field of fertility treatments.
• Fresenius Vamed manages projects and provides services for hos- pitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical manage- ment to total operational management.

SALES BY BUSINESS SEGMENT

Fresenius Vamed

5%

Fresenius Kabi

19%

Fresenius Medical Care

47%

Fresenius Helios

29%

H1 / 22: € 19.7 billion

Factsheet H1/ 22 © Fresenius SE & Co. KGaA - Investor Relations & Sustainability

| Factsheet H1/ 22

RELATIVE SHARE PRICE PERFORMANCE	DEVELOPMENT OF DIVIDENDS IN €
FRESENIUS SHARE VS. DAX

															0.88	0.92
110														0.84
													0.80
												0.75
100											0.62
										0.55
90								0,42	0.44
							0.37
80
70
30.12.2021	31.01.2022	28.02.2022	31.03.2022	30.04.2022	31.05.2022	30.06.2022	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

	DAX		Fresenius share

GROUP OUTLOOK 2022

		FY / 21 Base1		Targets 2022 2
				Low-to-mid
				single-digit per-
Sales, growth (cc)		€37,520 million		centage growth
				Low-to-mid
				single-digit per-
Net income 3, growth (cc)		€1,867 milion		centage decline

1. Before special items, including COVID-19 effects
2. Before special items, including estimated COVID-19 effects
3. Net income attributable to shareholders of Fresenius SE & Co. KGaA

For the outlook of the business segments please see the Investor News of August 2, 2022.

FRESENIUS SHARE / ADR

ANALYST RECOMMENDATIONS

FINANCING MIX OF THE FRESENIUS GROUP

Sustainability

Share

Securities code no.		578 560
ISIN	DE0005785604
Equal-weight / Hold /
Ticker symbol	FRE
Neutral	44%
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2022)	563,237,277
Market capitalization (June 30, 2022)		€16.3 billion	As of June 30, 2022

	Equity-neutral convertible bonds	2 %
	Commercial Paper	5%
	Schuldschein loans	6%
Buy /Outperform /	Other financial
Overweight 56%	liabilities	6%
	Lease liabilities 24%
			June 30, 2022: ~ € 28.4 billion

A/R Facility 1% EIB loan 1%

Bonds 55%

KGaA - Investor Relations &

FINANCIAL CALENDAR			CONTACT
		Dates
Meet the Management Fresenius Kabi		October 7, 2022
Report on 1st- 3rd quarter 2022		November 1, 2022

Please note that these dates could be subject to modifications.

www.fresenius.com/events-and-roadshows

Fresenius SE & Co. KGaA Else-Kröner-Straße1, 61352 Bad Homburg v. d. H. E-mail: [e-mail]

Internet: www.fresenius.de

Markus Georgi

Senior Vice President

Investor Relations & Sustainability

Telephone: +49 (0 ) 61 72 / 6 08-24 85

Telefax: +49 (0 ) 61 72 / 6 08-24 88

Follow us on Social Media:

linkedin.com/company/fresenius-investor-relations

twitter.com/Fresenius_IR

For more information please see the imprint on our corporate website.

Factsheet H1/ 22 © Fresenius SE & Co.